Status:
COMPLETED
Effects of Intrathecal Dexmedetomidine as an Adjuvant to Low Dose Hyperbaric 0.5% Bupivacaine
Lead Sponsor:
Sindh Institute of Urology and Transplantation
Conditions:
Post Operative Pain
Eligibility:
MALE
50-80 years
Phase:
PHASE4
Brief Summary
Patients will be enrolled in one of the two groups using a computer-generated random number table: Group I will receive 1.5 ml of 0.5% hyperbaric bupivacaine (7.5 mg). Group II will receive 1.2 mL of ...
Detailed Description
After approval of the synopsis and permission from the hospital ethics committee, all patients meeting the inclusion criteria will be included in the study. Patients will be instructed not to consume ...
Eligibility Criteria
Inclusion
- ASA I to ASA II
- Age 50 to 80 years old
- Height between 155cm and 175 cm
Exclusion
- History of spine surgery or the presence of an infectious focus on the back
- Patient's refusal to undergo a spinal anaesthesia
- Hypersensitivity to bupivacaine or dexmedetomidine
- Patients taking drugs of abuse or narcotic analgesics
- Diabetic neuropathy
- History of bleeding disorders
- Oral/intravenous anticoagulant therapy
- History of arrhythmias or labile hypertension
- Unco-operative patients
- Hearing defect
- ASA III and IV
- Central or peripheral nervous system disorders
- Severe hypovolemia
Key Trial Info
Start Date :
July 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 18 2022
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT05993975
Start Date
July 20 2021
End Date
February 18 2022
Last Update
October 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Syed Muhammad Abbas
Karachi, Sindh, Pakistan, 74200